Hematology

Medicine & Life Sciences

1. Multiple Myeloma 100%
2. B-Cell Chronic Lymphocytic Leukemia 50%
3. Survival 48%
4. Immunoglobulin Light-chain Amyloidosis 40%
5. Primary Myelofibrosis 39%
6. Amyloidosis 37%
7. Therapeutics 35%
8. Non-Hodgkin's Lymphoma 31%
9. Neoplasms 29%
10. Stem Cell Transplantation 27%
11. Lenalidomide 25%
12. Bone Marrow 25%
13. Lymphoma 25%
14. Plasma Cells 25%
15. Waldenstrom Macroglobulinemia 24%
16. Transplants 23%
17. Lymphoma, Large B-Cell, Diffuse 22%
18. Polycythemia Vera 22%
19. Rituximab 22%
20. Mutation 21%
21. Essential Thrombocythemia 21%
22. Monoclonal Gammopathy of Undetermined Significance 19%
23. B-Lymphocytes 19%
24. Acute Myeloid Leukemia 19%
25. Dexamethasone 17%
26. Progression-Free Survival 17%
27. Light 17%
28. T-Lymphocytes 17%
29. Bortezomib 16%
30. Drug Therapy 16%
31. Hodgkin Disease 16%
32. B-Cell Lymphoma 15%
33. Myelodysplastic Syndromes 15%
34. Cell Transplantation 14%
35. Melanoma 13%
36. Cytogenetics 13%
37. Stem Cells 13%
38. Leukemia 13%
39. Recurrence 12%
40. Paraproteinemias 12%
41. Clinical Trials 12%
42. Hematopoietic Stem Cell Transplantation 12%
43. Smoldering Multiple Myeloma 11%
44. Thalidomide 11%
45. Amyloid 11%
46. Precursor Cell Lymphoblastic Leukemia-Lymphoma 11%
47. POEMS Syndrome 11%
48. Follicular Lymphoma 11%
49. Allogeneic Cells 10%
50. Chimeric Antigen Receptors 10%
51. Cyclophosphamide 10%
52. Systemic Mastocytosis 10%
53. Hematologic Neoplasms 10%
54. Psychological Burnout 10%
55. Leukemia, Myelomonocytic, Chronic 10%
56. Melphalan 9%
57. Confidence Intervals 9%
58. Serum 9%
59. Risk Management 9%
60. Hematopoietic Stem Cells 9%
61. Proteins 9%
62. Transplantation 8%
63. ibritumomab tiuxetan 8%
64. Population 8%
65. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8%
66. Myeloproliferative Disorders 8%
67. Lymphocytes 8%
68. Genes 7%
69. Pharmaceutical Preparations 7%
70. Chromosome Aberrations 7%
71. Immunotherapy 7%
72. Immunoglobulin Light Chains 7%
73. Lymphocytosis 7%
74. Prednisone 7%
75. Incidence 7%
76. Mortality 7%
77. Amyloidosis, Hereditary, Transthyretin-Related 7%
78. Graft vs Host Disease 7%
79. Mantle-Cell Lymphoma 7%
80. pomalidomide 7%
81. Kidney 7%
82. PCI 32765 7%
83. Biopsy 7%
84. Fluorescence In Situ Hybridization 7%
85. Safety 7%
86. ixazomib 7%
87. Biomarkers 6%
88. Immunoglobulin M 6%
89. Thrombocytosis 6%
90. Anemia 6%
91. Lymphoproliferative Disorders 6%
92. Proteasome Inhibitors 6%
93. Venous Thromboembolism 6%
94. Physicians 6%
95. Disease Progression 6%
96. Monocytes 6%
97. Radioimmunotherapy 6%
98. Immunoglobulins 6%
99. Thrombosis 5%
100. Monoclonal Antibodies 5%